Vantive, a major US-based medtech firm, has announced plans to build a new factory in Ħal Far focused on developing products for renal patients.

Announcing the €150 million investment today, Senior Director Brian Tabone said the factory is expected to start operating in 2029 and employ around 250 people by the time it is fully operational.

The Maltese Government has hailed this investment as one of the largest ever foreign direct investments in Maltese history.

Vantive used to form part of Baxter, which has long had a presence in Malta, but launched as a standalone company in 2025 following its acquisition by funds managed by Carlyle, one of the world’s largest private equity firms.

It focuses on therapies for chronic kidney disease and acute kidney injury.